Overview
The Functional Assessment of Cancer Therapy – Lymphoma (FACT-Lym) was developed to address health-related quality-of-life issues for NHL patients. Items for the FACT lymphoma subscale were generated from healthcare provider interviews, published literature, and content validity patient interviews. The scale was validated on a sample of 84 NHL patients, with additional measures at baseline (T1), 3–7 days (T2), and 8–12 weeks (T3). Item correlations, expert relevance ratings, and patient input on content shortened the initial 22-item lymphoma subscale to 15 items. The validation sample included 56% female, 76.2% white, 60% indolent disease, and 85% receiving treatment. Internal consistency coefficients for the subscale (.79, .85, and .84 T1–T3) and test-retest stability (.84) indicated good reliability. Correlations between the lymphoma scale and SF-36 physical (𝑟 = .62) and mental (𝑟 = .48) summary scores reflect concurrent validity. Responsiveness to ECOG performance status and treatment status exceeded established FACT subscale scores. The subscale differentiated patients’ retrospective ratings of change in each of the three groups (better; unchanged; worse), 𝑃 < 0.001.
MEASURE NAME:
Functional Assessment of Cancer Therapy – Lymphoma (FACT-Lym)
VERSION:
4
NUMBER OF ITEMS:
42
PATIENT POPULATION:
Lymphoma patients 18 years and older
RECALL PERIOD:
Past 7 days
RESPONSE SCALE:
5 point Likert-type scale
DATA COLLECTION:
Paper and electronic
ADMINISTRATION:
Self-administration and interview when applicable
SUBSCALE DOMAINS:
Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Lymphoma Subscale
TIME FOR COMPLETION:
10-15 minutes
SCORING:
Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available.
RELATED MEASURES:
Language Availability
Available translations of the FACT-Lym can be obtained by registering for permission. Users are not permitted to translate the FACT-Lym without permission from FACIT.org. Permission from FACIT.org to translate the FACT-Lym may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system.
Please contact us for more information.
Licensing
Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained.
Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use.
To license an available version of this measure for commercial or non-commercial use, please complete our registration form. All of the information provided in the form will be kept strictly confidential. For questions, please contact us.
Selected References
Hlubocky, F., Webster, K., Cashy, J., Beaumont, J., & Cella, D. The development and validation of a measure of health-related quality of life for non-hodgkin’s lymphoma: the functional assessment of cancer therapy—lymphoma (FACT-Lym). Lymphoma 2013; Article ID 147176. doi: 10.1155/2013/147176.
Hlubocky, F., Webster, K., Beaumont, J., Cashy, J., Paul, D., Abernathy, A., Syrjala, K., Von Roenn, J., & Cella, D. A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Lymphoma Symptom Index. Leukemia & Lymphoma 2013; 54(9): 1942-1946. doi: 10.3109/10428194.2012.76297.
Pettengell, R., Donatti, C., Hoskin, P., Poynton, C., Kettle, P., Hancock, B., Johnson, S., Dyer, M., Rule, S., Walker, M., & Wild, D. The impact of follicular lymphoma on health-related quality of life. Annals of Oncology 2008; 19: 570–576. doi: 10.1093/annonc/mdm543.
Cheson B.D., Trask P.C., Gribben J.G., et al. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. Ann Hematol. 2017;96(2):253-259. doi:10.1007/s00277-016-2878-5.
Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320.
Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232.
Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85.
Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191.
Related Measures